Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. Other options that complement the induction regimen with favorab...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimopoulos, Meletios A., Špička, Ivan, Quach, Hang, Oriol, Albert, Hájek, Roman, Garg, Mamta, Beksac, Meral, Bringhen, Sara, Katodritou, Eirini, Chng, Wee-Joo, Leleu, Xavier, Iida, Shinsuke, Mateos, María-Victoria, Morgan, Gareth, Vorog, Alexander, Labotka, Richard, Wang, Bingxia, Palumbo, Antonio, Lonial, Sagar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768338/
https://www.ncbi.nlm.nih.gov/pubmed/33021870
http://dx.doi.org/10.1200/JCO.20.02060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768338/
https://www.ncbi.nlm.nih.gov/pubmed/33021870
http://dx.doi.org/10.1200/JCO.20.02060

Ejemplares similares